HomeNYSE:LLY

NYSE:LLY

Why Big Pharma is Betting on Telehealth Strategies

Why Big Pharma is Betting on Telehealth Strategies

September 6, 2024

Roche Weight-Loss Drug Shows Promise, Impacting Rivals

Roche Weight-Loss Drug Shows Promise, Impacting Rivals

July 17, 2024

Eli Lilly to Invest $5B+ in Indiana Plant for Zepbound and Mounjaro

Eli Lilly to Invest $5B+ in Indiana Plant for Zepbound and Mounjaro

May 24, 2024

Eli Lilly Raises Sales Outlook by $2B Amid Weight-Loss Drug Surge

Eli Lilly Raises Sales Outlook by $2B Amid Weight-Loss Drug Surge

April 30, 2024

Lilly Teams Up with Amazon to Deliver Drugs Such as Zepbound

Lilly Teams Up with Amazon to Deliver Drugs Such as Zepbound

March 14, 2024

Evaluating Eli Lilly: A Deep Dive into the Biotech Stock’s Prospects

Evaluating Eli Lilly: A Deep Dive into the Biotech Stock’s Prospects

January 5, 2024

Eli Lilly Stock Declines as Patients Experience Weight Gain Following Discontinuation of Zepbound

Eli Lilly Stock Declines as Patients Experience Weight Gain Following Discontinuation of Zepbound

December 12, 2023

Eli Lilly Secures Second FDA Approval for Jaypirca in Lymphoma Treatment

Eli Lilly Secures Second FDA Approval for Jaypirca in Lymphoma Treatment

December 4, 2023

Eli Lilly Secures FDA Approval for Obesity Drug Competing with Wegovy and Ozempic

Eli Lilly Secures FDA Approval for Obesity Drug Competing with Wegovy and Ozempic

November 8, 2023